HOME >> BIOLOGY >> NEWS
Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers

Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.

Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.

"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.

Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly intere
'"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
European Organisation for Research and Treatment of Cancer
8-Nov-2006


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme shreds Alzheimers protein
5. Enzyme defect leads to hyperinsulinism
6. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
7. Enzyme crystal structure reveals unexpected genome repair functions
8. Enzyme inhibitors block replication of SARS virus
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2020)... ... April 27, 2020 , ... ... was started by three teenagers with an idea to help millions of people ... the time of great need and suffering, an outlet has been created for ...
(Date:4/22/2020)... ... April 20, 2020 , ... RCH Solutions (RCH ), a global ... announces the hiring of Michael Wlodarczyk as Director of Sales and Business Development. Based ... grow the company’s already strong presence across the Northeast. , “We continue to see ...
(Date:4/18/2020)... ... April 16, 2020 , ... SIRION Biotech GmbH , a world ... it will present a company update on its work expediting gene therapy research and ... on April 22 and 23. Dieter Lingelbach, the Company’s Chief Operating Officer, will also ...
Breaking Biology News(10 mins):
(Date:4/26/2020)... ... April 23, 2020 , ... Indegene Omnipresence, Inc. ... providing applications and services for use on Microsoft Azure. The customer experience management ... up online for a built-for-purpose customer engagement capability to use in their commercial ...
(Date:4/22/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... April 20, ... ... Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder and ... the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping ...
(Date:4/22/2020)... ... April 21, 2020 , ... ... work through COVID-19. Many clinical trial teams are working remotely and have paused ... wants to help researchers continue their research during this uncertain time by giving ...
(Date:4/7/2020)... ... April 06, 2020 , ... Gateway Genomics , leading developer ... SneakPeek Early Gender DNA Tests sold in March, just months after attaining ... an ecommerce product, where a mom could order her kit online, collect a DNA ...
Breaking Biology Technology:
Cached News: